External Validity of a Randomized Trial in Patients With a Femoral Neck Fracture

Hip Fracture Clinical Trial

— EXVAL  

Official title:

External Validity of a Randomized Controlled Trial in Patients With a Femoral Neck Fracture

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02362971
• Other study ID #: External validity
• Status: Active, not recruiting
• Phase: N/A
• First received: January 26, 2015
• Last updated: August 29, 2016
• Start date: September 2009
• Est. completion date: October 2027

Study information

• Verified date: August 2016
• Source: Danderyd Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Sweden: Swedish National Council on Medical Ethics
• Study type: Observational

Clinical Trial Summary

The aim of this study is to evaluate the external validity of a randomized controlled trial comparing choice of hip arthroplasty for elderly patients (>80 years) with a displaced femoral neck fracture.

The hypotheses are that patient reported hip function, quality of life are better and healthier in those included in the randomized controlled trial than those excluded. The external validity of the randomized controlled trial is acceptable.

A prospective randomized controlled trial is planned and patients with a displaced femoral neck fracture will be included and randomized between either a hemiarthroplasty or total hip arthroplasty. All patients screened will be included in a prospective cohort study for evaluation of the external validity of the randomized controlled trial. The prospective cohort study will consist of 3 different groups.

Patients included in the randomized controlled trial will form group 1. Patients eligible for the randomized controlled trial but did not give their informed consent and therefore excluded, form group 2.

Patients with a femoral neck fracture which by any reason were excluded form group 3.

Primary endpoint is patient-reported hip function (Harris hip score) and pain on the operated extremity evaluated with VAS (Visual Analogue Scale) and patient reported quality of life evaluated with EuroQol (EQ-5D). Secondary outcome measurement are the frequency of the complications, periprosthetic fracture, dislocation, revision surgery due to wound infection (deep and superficial) and loosening of the components. Baseline data, age, sex, comorbidity, cognitive status, weight, height, motor function, complications and reoperations. Follow up is performed 1-2 years after surgery.

Group 1 is followed up in the ongoing randomized controlled trial by visits to the orthopedic department at Danderyd Hospital. Group 2 and 3 are followed up by telephone interview 1-2 year after surgery.

Description:

The aim of this study is to evaluate the external validity of a randomized controlled trial comparing choice of hip arthroplasty for elderly patients (>80 years) with a displaced femoral neck fracture.

The hypotheses are:

1. The patient reported hip function and quality of life are better in those included in the randomized controlled trial than those excluded.

2. Patients included in the study are healthier than those excluded.

3. The external validity of the randomized controlled trial is acceptable, defined as the difference between patients that provide and do not provide their informed consent do not reach clinical significance (a mean difference in Harris hip score of 10 points).

All patients above 80 years old with an acute displaced femoral neck fracture at Danderyds hospital AB during 2009-2016 will be screened and asked for participation in a randomized controlled trial. Those who fulfill the criteria for inclusion and give their informed consent are enrolled in the randomized controlled trial. Patients that will not give their informed consent and those which do not fulfill the inclusion criteria are enrolled in a prospective cohort study for evaluation of the external validity.

The prospective cohort study will consist of 3 different groups. Patients included in the randomized controlled trial study will form group 1. Patients eligible for the randomized controlled trial but did not give their informed consent and therefore excluded, form group 2.

Patients with a femoral neck fracture which by any reason were excluded form group 3.

Follow-up is performed 1-2 years after surgery. Inclusion criteria in the randomized controlled trial.

1. Age above 80 years 2. Acute (<36h) displaced femoral neck fracture. 3. Independent walker

4. Abscence of cognitive impairment (Pfeiffer test >7) 5. Did not fulfill any exclusion criteria Exclusion criteria in the randomized controlled trial

1. Patient with osteoarthritis or rheumatoid arthritis in the fractured hip

2. Pathological fracture

3. Non walker

4. Cognitive impairment (Short Portable Mental Questionnaire <7)

5. Contraindication to total hip replacement due to wound, patients with comorbidities, deemed not suitable for a total hip replacement by the anesthesiologist, severe coagulation disorder, and severe drug abuse.

6. Deemed unsuitable for inclusion by other reason.

1. Primary endpoint is patient-reported hip function (Harris hip score) and pain on the operated extremity evaluated with VAS (Visual Analogue Scale)

2. Patient reported quality of life evaluated with EQ-5D.

Secondary outcome:

1. Secondary outcome measurement are the frequency of the complications, periprosthetic fracture, dislocation, revision surgery due to wound infection (deep and superficial) and loosening of the components.

2. Baseline data, age, sex, comorbidity, cognitive status, weight, height, motor function and complications and reoperations.

Secondary outcome measurements are obtained in the medical records.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 900
• Est. completion date: October 2027
• Est. primary completion date: October 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 80 Years and older

Eligibility

Inclusion Criteria randomized controlled trials:

• Age above 80 years

• Acute (<36h) displaced femoral neck fracture.

• Independent walker

• Abscence of cognitive impairment (Short Portable Mental Questionnaire >7points)

• Did not fulfill any exclusion criteria

Exclusion Criteria randomized controlled trial:

• Patient with osteoarthritis or rheumatoid arthritis in the fractured hip

• Pathological fracture

• Non walker

• Cognitive impairment (Short Portable Mental Questionnaire <7points)

• Contraindication to total hip replacement due to wound, patients with comorbidities, deemed not suitable for a total hip replacement by the anesthesiologist, severe coagulation disorder, and severe drug abuse.

• Deemed unsuitable for inclusion by other reason.

Inclusion into prospective cohort study

• Included into the randomized controlled trial.

• Did not give their informed consent for participation in the randomized controlled trial.

• Patients above 80 years of age excluded from participation in the randomized controlled trial due to fulfillment of exclusion criteria or did not fulfill inclusion criteria.

Exclusion into prospective cohort study

• Age below 80 years of age.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Femoral Neck Fracture
• Femoral Neck Fractures
• Fractures, Bone
• Hip Fracture
• Hip Fractures

Locations

Country	Name	City	State
Sweden	Orthopaedic department, Danderyd Hospital	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Danderyd Hospital

Country where clinical trial is conducted

Sweden, 

References & Publications (6)

Evidence-based health care: a new approach to teaching the practice of health care. Evidence-Based Medicine Working Group. J Dent Educ. 1994 Aug;58(8):648-53. Review. — View Citation

Gao H, Liu Z, Xing D, Gong M. Which is the best alternative for displaced femoral neck fractures in the elderly?: A meta-analysis. Clin Orthop Relat Res. 2012 Jun;470(6):1782-91. doi: 10.1007/s11999-012-2250-6. Epub 2012 Jan 26. — View Citation

Petersen MK, Andersen KV, Andersen NT, Søballe K. "To whom do the results of this trial apply?" External validity of a randomized controlled trial involving 130 patients scheduled for primary total hip replacement. Acta Orthop. 2007 Feb;78(1):12-8. — View Citation

Pibouleau L, Boutron I, Reeves BC, Nizard R, Ravaud P. Applicability and generalisability of published results of randomised controlled trials and non-randomised studies evaluating four orthopaedic procedures: methodological systematic review. BMJ. 2009 Nov 17;339:b4538. doi: 10.1136/bmj.b4538. Review. — View Citation

Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005 Jan 1-7;365(9453):82-93. — View Citation

van den Bekerom MP, Hilverdink EF, Sierevelt IN, Reuling EM, Schnater JM, Bonke H, Goslings JC, van Dijk CN, Raaymakers EL. A comparison of hemiarthroplasty with total hip replacement for displaced intracapsular fracture of the femoral neck: a randomised controlled multicentre trial in patients aged 70 years and over. J Bone Joint Surg Br. 2010 Oct;92(10):1422-8. doi: 10.1302/0301-620X.92B10.24899. Erratum in: J Bone Joint Surg Br. 2011 Jan;93(1):140. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Harris hip score	Hip function as a patient reported outcome measurement	Up to 2 years	No
Secondary	Baseline data (Preoperative baseline data obtained at admission to the hospital)	Age, sex, date of surgery, type of surgical treatment, surgical approach, time, level of competence of the treating surgeon, American Society of Anesthesiologists grade determined by treating anesthesiologist, surgical time, patients weight and length	1 day	No
Secondary	Mortality		up to 2 years	No
Secondary	Complications (Any reason to reoperation)	Any reason to reoperation most commonly prosthetic dislocation, deep infection, periprosthetic dislocation	up to 4 years years	No
Secondary	EQ-5D	Health related quality of life, patient reported outcome	up to 2 years	No